[Pharmacological studies on a new penicillin group antibiotic, sodium 6-[D(-)-alpha-(4-ethyl-2, 3-dioxo-1-piperazinecarboxamido)-alpha-phenylacetamido] penicillanate (T-1220). II. Effect on circulatory system and blood (author's transl)].
D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D001769:Blood / Q000187:drug effects*; D001775:Blood Circulation / Q000187:drug effects*; D001777:Blood Coagulation / Q000187:drug effects; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D004562:Electrocardiography; D004573:Electrolytes / Q000652:urine; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects; D007677:Kidney Function Tests; D008297:Male; D051379:Mice; D010406:Penicillins / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D012119:Respiration / Q000187:drug effects
D004573:Electrolytes; D010406:Penicillins; D010879:Piperazines; D000667:Ampicillin